Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection

OBJECTIVES: To evaluate the safety, tolerability and immunogenicity of three different doses (5, 25 and 50 µg) of the novel antituberculous vaccine RUTI compared to placebo in subjects with latent tuberculosis infection. METHODS AND FINDINGS: Double-blind, randomized, placebo-controlled Phase II Cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Nell, Andre S., D’lom, Eva, Bouic, Patrick, Sabaté, Montserrat, Bosser, Ramon, Picas, Jordi, Amat, Mercè, Churchyard, Gavin, Cardona, Pere-Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935928/
https://www.ncbi.nlm.nih.gov/pubmed/24586912
http://dx.doi.org/10.1371/journal.pone.0089612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935928/
https://www.ncbi.nlm.nih.gov/pubmed/24586912
http://dx.doi.org/10.1371/journal.pone.0089612

Ejemplares similares